Navigation Links
Stallergenes S.A.: Positive Results From a Phase IIb/III Clinical Trial on the House Dust Mite Desensitization Tablet
Date:4/29/2009

ANTONY, France, April 29 /PRNewswire-FirstCall/ -- Stallergenes S.A. announces the release of the first year outcome of its phase IIb/III clinical trial (VO 57.07) on a sublingual house dust mite desensitization tablet.

"We are very pleased with the outcome of this study, which is the first large study to ever demonstrate the efficacy of house dust mites allergen in treating perennial allergic rhinitis. Furthermore, the unexpected quick onset of action and the good safety profile are addressing the needs of patients with moderate to severe forms of the disease. This study will be pivotal in the European registration process of our house dust mites sublingual tablet, and the basis for further developments in our program" states Albert Saporta, Chairman and CEO of Stallergenes. "This study is a genuine landmark which confirms desensitization as a new therapeutic class in the management of allergic respiratory disorders. Stallergenes has been consolidating its leadership in this field through its innovative and development capabilities".

Stallergenes has been conducting a phase IIb/III clinical trial, with a sublingual tablet in adults suffering from moderate to severe persistent allergic rhinitis to house dust mites, including 509 patients, over seven countries, with a full year of treatment from January to December 2008. This study compared two treated groups, one with a daily intake of 300 IR[1] sublingual tablet, the other of 500 IR, with a placebo group. The endpoint was the adjusted average symptom score on nasal symptoms assessed during the three last months of the year.

The two treated groups have demonstrated a highly significant statistical difference on the primary endpoint versus the placebo group (p less than or equal to 0.0136), with no difference between the two treated groups. In the different groups, use of rescue medication was allowed throughout the period. The adjusted avera
'/>"/>

SOURCE Stallergenes
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. STALLERGENES: Oralair(R) Grasses Obtains a Pediatric MA(1) in Germany
2. Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber
3. Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C
4. Addrenex Pharmaceuticals Reports Positive Results in Second Phase 3 Study of ADHD Medication
5. Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial
6. Study Data Show Positive European Experience With DuraHeart Left Ventricular Assist Device for Advanced Stage Heart Failure Patients
7. Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
8. Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity
9. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
10. DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program
11. Cardiums InnerCool Announces Positive Benefits of Cooling During Robotic-Assisted Prostate Surgery Published in Urology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 17, 2014  ImmunoCellular Therapeutics, Ltd. ... Patent and Trademark Office (USPTO) has issued a ... dendritic cell-based immunotherapeutic vaccine targeting six tumor antigens ... of US Patent No. 8,871,211, which issued October ... by administering a dendritic cell composition comprising peptide ...
(Date:12/15/2014)... , December 15, 2014 ... Am 19. und 20. Februar sind ... Aegate SAFE MEDICINE ECOSYSTEM PARTNER PROGRAMM ™ ... zu besuchen. Diese Tagung soll ... die Möglichkeit geben, die neue profitablen Unternehmensdienstleistungen, ...
(Date:12/15/2014)... -- BerGenBio AS, a biopharmaceutical company focused ... today announces that it has raised NOK90 million (c. ... existing investors. BerGenBio will use the proceeds ... pipeline of innovative cancer therapeutics, in particular an enlarged ... a first-in-class selective Axl kinase inhibitor, which is currently ...
Breaking Medicine Technology:ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2BerGenBio Completes NOK90 Million Fundraising 2
... Anaphore Inc. today announced that the company ... Corporation (Osaka, Japan) for the research, development and commercialization ... The partnership will be based on ... called Atrimers(TM ) with binding domains that can ...
... MISSISSAUGA, Ontario, Dec. 13, 2010 Valeant Pharmaceuticals International, ... announced that Robert A. Ingram, Valeant,s lead independent director, ... replacing William M. Wells, who has resigned from the ... About Valeant Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is ...
Cached Medicine Technology:Anaphore Enters R&D Partnership with Mitsubishi Tanabe Pharma to Develop and Commercialize Novel Protein Pharmaceuticals for Autoimmune Disorders 2Anaphore Enters R&D Partnership with Mitsubishi Tanabe Pharma to Develop and Commercialize Novel Protein Pharmaceuticals for Autoimmune Disorders 3
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. ... diseases, one worrisome phenomenon is when an illness that originated ... known as zoonosis -- is not uncommon and keeps researchers ... animal-borne disease might make inroads into the human population. ... and the culprits in this case were guinea pigs. More ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, 2014 (HealthDay ... health, but a growing body of evidence shows the ancient ... In fact, the benefits were similar to those of ... Chu, a doctoral candidate at Harvard University,s Health Policy Program ... that people randomly assigned to take yoga classes saw improvements ...
(Date:12/15/2014)... 15, 2014 Main Street Dental Team ... weighing in on a new study providing evidence on ... oral hygiene of children. , Sufficient enough evidence already ... as pop or juice drinks, with the onset of ... is whether drinks listed as 100% fruit juice, meaning ...
(Date:12/15/2014)... Steven Reinberg HealthDay Reporter ... new study should reassure the millions of American women who ... breast cancer. "There is no association between migraine and ... professor of medicine at Harvard Medical School. "There is no ... there is no protective effect either." About 18 percent ...
(Date:12/15/2014)... OR (PRWEB) December 15, 2014 ... seeks to bring attention to restrictive state laws ... position paper on this important area of public ... Laws Can Compromise the Integrity of Independent Review, ... and access of independent peer review determinations can ...
Breaking Medicine News(10 mins):Health News:Guinea Pigs Can Be Source of Serious Strep Infection 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 3Health News:Yoga May Cut Heart Disease Risk Factors 2Health News:Yoga May Cut Heart Disease Risk Factors 3Health News:Main Street Dental Team, Unionville’s Most Innovative Dental Clinic, Comments on New Study Relating Pure Fruit Juice to Poor Oral Hygiene 2Health News: No Link Between Migraine, Breast Cancer Risk, Study Says 2Health News:NAIRO Calls for Higher Quality Independent Peer Review By Ending Restrictive State Laws 2
... , THURSDAY, Jan. 20 (HealthDay News) -- Emotions can ... products such as airbags, vaccines and smoke detectors, researchers ... they learn that a safety product may carry certain ... airbags sometimes injure or kill. But just because these ...
... HealthDay Reporter , THURSDAY, Jan. 20 (HealthDay News) -- ... the help of aides Wednesday, bodes well for her ... will be moved Friday, just 13 days after a ... University Medical Center in Tucson indicate that the Arizona ...
... paper published Jan. 21 in the journal Science , ... Blossom Damania, PhD, has shown for the first time that ... a key molecule involved in the human immune response. ... Kenan, Jr. Distinguished Professor, Jenny Ting, PhD. First ...
... support system in the first year after diagnosis are less ... to new research from Vanderbilt-Ingram Cancer Center (VICC) and the ... author Meira Epplein, Ph.D., assistant professor of Medicine at VICC, ... of Clinical Oncology. Patients in the study ...
... have found that when patients and providers speak ... better health care quality. The findings were based ... Johnson Foundation,s Latino Health Survey. Understanding the ... important public health implications for providing services in ...
... By Amanda Gardner HealthDay Reporter , THURSDAY, ... be behaving very differently depending on what side of ... example, H1N1 ("swine") flu still predominated in Britain, where 112 ... flu patients, and some doctors report running out of vaccine, ...
Cached Medicine News:Health News:Emotions May Sidetrack Use of Safety Devices 2Health News:Rep. Giffords Standing Up, Set to Begin Rehab Friday 2Health News:Rep. Giffords Standing Up, Set to Begin Rehab Friday 3Health News:Viral protein mimic keeps immune system quiet 2Health News:Strong social ties benefit breast cancer patients 2Health News:Speaking the same language means better health care quality, Wayne State University study finds 2Health News:H1N1 Flu Is Raging in Britain; Could U.S. Be Next? 2Health News:H1N1 Flu Is Raging in Britain; Could U.S. Be Next? 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: